Gilead Q2 revenues flat; earnings up 3.5%; guidance raised

Gilead Sciences (NASDAQ:GILD) Q2 results ($M): Revenues: 5,685 (+0.7%); Product sales: 5,607 (+1.2%); HIV sales: 4,041 (+10.3%).

Key product sales: Biktarvy: 1,116 (+999%); Genvoya: 980 (-15.5%); Truvada: 718 (-6.1%); Odefsey: 387 (+0.5%); Descovy: 358 (-11.2%); Yescarta: 120 (+76.5%).

Net income: 1,880 (+3.5%); non-GAAP net income: 2,331 (-6.5%); EPS: 1.47 (+5.8%); non-GAAP EPS: 1.82 (-4.7%).

2019 guidance: Product sales: $21.6B – 22.1B from $21.3B – 21.8B.

Shares up 1% after hours.

Gilead Sciences (NASDAQ:GILD) Q2 results ($M): Revenues: 5,685 (+0.7%); Product sales: 5,607 (+1.2%); HIV sales: 4,041 (+10.3%).

Key product sales: Biktarvy: 1,116 (+999%); Genvoya: 980 (-15.5%); Truvada: 718 (-6.1%); Odefsey: 387 (+0.5%); Descovy: 358 (-11.2%); Yescarta: 120 (+76.5%).

Net income: 1,880 (+3.5%); non-GAAP net income: 2,331 (-6.5%); EPS: 1.47 (+5.8%); non-GAAP EPS: 1.82 (-4.7%).

2019 guidance: Product sales: $21.6B – 22.1B from $21.3B – 21.8B.

Shares up 1% after hours.

https://seekingalpha.com/news/3483705-gilead-q2-revenues-flat-earnings-3_5-percent-guidance-raised